Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
Rain Therapeutics Inc. (NasdaqGS: RAIN), a biotechnology firm focused on precision oncology, will announce its third-quarter financial results for the period ending September 30, 2022, on November 10, 2022. The report will include updates on its lead product candidate, milademetan, an oral inhibitor targeting the MDM2-p53 complex. A conference call is scheduled for 2:00 PM PT (5:00 PM ET) on the same day to discuss the results and business developments.
- Upcoming third-quarter financial results expected to provide insights on business progress.
- Continuation of development of milademetan, a potential treatment in precision oncology.
- None.
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced it will report financial results for the third quarter ended September 30, 2022 and highlights of recent progress on Thursday, November 10, 2022. On that day, management will host a conference call and webcast at 2:00 pm PT (5:00 pm ET) to discuss the Company’s business and financial results.
Conference Call and Webcast Details:
Date: November 10, 2022
Time: 2:00 PT (5:00 pm ET)
Dial In Numbers: 1 (877) 704-4453 (U.S. Toll Free) / 1 (201) 389-0920 (International)
Conference ID: 13733093
Webcast Link: https://edge.media-server.com/mmc/p/2vzj7av9
Replay of the call will be available by visiting the "Events" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com
Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com
FAQ
When will Rain Therapeutics report its third-quarter financial results?
What is milademetan?
What time is the conference call for Rain Therapeutics' financial results?
How can investors access the financial results call replay?
